ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 0250

Effectiveness of Tuberculosis Preventive Treatment in Patients with Rheumatic Diseases: A Global Meta-analysis of Cohort Studies
Abstract Number: 0251

T-SPOT.TB and TST in Diagnosing Active Tuberculosis in Patients with Rheumatic Immune Diseases: A Fully Paired Comparative Diagnostic Test Accuracy Study
Abstract Number: 0252

Prospective Study of Severe Infectious Events and Immune Reconstitution After Rituximab in Autoimmune Diseases
Abstract Number: 0253

Outcomes of Respiratory Syncytial Virus Infection in Patients with Systemic Autoimmune Rheumatic Diseases
Abstract Number: 0254

Rheumatic Manifestations in Patients with Hansen’s Disease Treated with Multidrug Antibiotic Therapy
Abstract Number: 0255

“Rheum” to Improve: Have Patients Attending the Young Adult Systemic Erythematosus (YASLE) Clinic Received All Appropriate Vaccinations? A Quality Improvement Initiative
Abstract Number: 0256

Anti-TNF Therapy as a Potential Risk of Leishmania Infections
Abstract Number: 0257

High Prevalence of Strongyloides Antibodies in Patients at Risk for Dissemination. A Call for Action
Abstract Number: 0258

Nationwide Analysis of Adult Non-Gonococcal Bacterial Septic Arthritis Hospitalizations from the National Inpatient Sample 2016 to 2020
Abstract Number: 0259

Whipple’s Disease in Patients Initially Diagnosed with Rheumatic Diseases: A Case Series
Abstract Number: 0260

National Survey on Patient’s Knowledge and Drivers of Human Papillomavirus (HPV) Vaccination in Immune-mediated Inflammatory Diseases (IMIDs)
Abstract Number: 0261

Clinical Implications, Bacterial Profiles, and Patient Outcomes in Hospitalized Patients with Autoimmune Rheumatic Diseases
Abstract Number: 0262

Bartonella Endocarditis as an Important Mimic of ANCA Associated Vasculitis: Results of a Large Single Center Descriptive Analysis
Abstract Number: 0263

Characteristics and Coinfections of Diffuse Alveolar Hemorrhage in Rheumatic Patients
Abstract Number: 0264

Clinical Value of Metagenomic Next-generation Sequencing in Patients with Connective Tissue Disease Co-infections: A Single-center Study from Southern Hospital in China

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].